Oxygen therapy shows promise in brain cancer fight

NCT ID NCT03862430

Ongoing Disease control Sponsor: NuvOx LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. NanO2 is designed to deliver more oxygen to tumors, which may make radiation work better. About 87 adults will take part, and researchers will track how long the cancer stays under control and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Atlantic Health System

Summit, New Jersey, 07901, United States
Center for Neurosciences

Tucson, Arizona, 85718, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Providence St. John's Cancer Institute

Santa Monica, California, 90404, United States
Saint Luke's Cancer Institute

Kansas City, Missouri, 64111, United States
St. Francis Medical Center, OSF Healthcare

Peoria, Illinois, 61637, United States
UC Irvine Health- Chao Family Comprehensive Cancer Center

Orange, California, 92868, United States
University Hospitals Seidman Cancer Center

Cleveland, Ohio, 44106, United States
University of Arizona

Tucson, Arizona, 85719, United States
Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.